Ultrasound System 2300

The Ultrasound System 2300 is a versatile diagnostic ultrasound platform employing multiple imaging modes and transducers for diverse clinical applications, including image-guided procedures. This iteration enhances its utility through a software enhancement that expands application availability across configurations and introduces an AI-powered Prostate Volume Assist feature to improve the efficiency of prostate volume measurements.

The BK Medical Ultrasound System 2300 is a mobile, software-controlled diagnostic ultrasound system designed for use by trained healthcare professionals. Its core purpose is to provide ultrasound imaging for a wide array of clinical applications, facilitate the analysis of human body fluid flow using Doppler principles, and offer guidance for puncture and biopsy procedures. The system employs a comprehensive suite of ultrasound technologies, including 2D (B-Mode) with Tissue Harmonic Imaging, M-Mode, Pulsed Wave Doppler (PWD), Color Flow Mapping (CFM), Power Doppler, Contrast Imaging, Continuous Wave (CW) Doppler, and Strain Elastography, functioning across diverse medical fields such as fetal imaging, abdominal studies, pediatrics, intra-operative scenarios (including neurosurgery and laparoscopy), small organ assessment, and cardiac examinations. Available in several configurations (bk3000, bk5000, bkActiv) optimized for specific clinical needs like urology, general surgery, and anesthesiology, the Ultrasound System 2300 utilizes various multi-frequency transducers. This specific device iteration focuses on a software enhancement that extends several clinical applications (e.g., Cardiac Adult, Fetal, Trans-rectal) and their compatible transducers to the bkActiv configuration. A key scientific and technological advancement is the introduction of the Prostate Volume Assist (PVA), an artificial intelligence-driven software feature aimed at enhancing workflow efficiency for prostate volume measurements by automating initial caliper placement. Performance results from testing showed PVA's automated volume estimates deviated by approximately 7% to 11% (depending on the transducer used) on average from manual expert measurements, successfully meeting the pre-defined accuracy criteria. The system also incorporates new TP Needle Guide Supporting software to improve visualization during biopsy procedures.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the Prostate Volume Assist (PVA) algorithm account for anatomical variability in prostates across different patient populations beyond the tested European demographic?; What specific quantitative improvements in procedure time or user workload does the PVA feature offer compared to traditional manual prostate volume measurement in a clinical setting?; For the TP Needle Guide Supporting software, what is the reported accuracy of the visualized biopsy lines in relation to actual needle placement during prostate biopsy procedures?; Given the expansion of applications to the bkActiv configuration, were any specific human factors or usability studies conducted to ensure optimal performance with its glass user interface across these newly enabled clinical uses?; What are the computational requirements and processing times for the AI-driven Prostate Volume Assist feature, and how might these impact the real-time clinical workflow?